Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Expenses (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Operating Expenses for 7 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For Q3 2025, Operating Expenses rose 42.28% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $6.5 million, up 6.03%, while the annual FY2024 figure was $5.6 million, 56.54% down from the prior year.
  • Operating Expenses hit $1.9 million in Q3 2025 for Cyclerion Therapeutics, up from $1.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $19.2 million in Q2 2021 and bottomed at $1.3 million in Q4 2024.
  • Average Operating Expenses over 5 years is $6.3 million, with a median of $3.3 million recorded in 2023.
  • Year-over-year, Operating Expenses plummeted 86.43% in 2023 and then soared 42.28% in 2025.
  • Cyclerion Therapeutics' Operating Expenses stood at $14.9 million in 2021, then crashed by 70.04% to $4.5 million in 2022, then crashed by 59.71% to $1.8 million in 2023, then dropped by 27.35% to $1.3 million in 2024, then skyrocketed by 44.25% to $1.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.9 million, $1.8 million, and $1.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.